
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Keywords: Alectinib: (PubMED CID: 49806720); Brigatinib: (PubMED CID: 68165256); Ceritinib: (PubMED CID: 57379345); Crizotinib (PubMED CID: 11626560); Entrectinib: (PubMED CID: 25141092); Lorlatinib: (PubMed CID: 71731823); ALK+-NSCLC; ALK-positive non-small cell l